Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Biochemical Journal

• Publication date

  2003-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1042/BJ20021880PMID 12723974PMCID PMC1223537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen activator inhibitor-1.

  2004cited by this paper
• Mutational analysis of plasminogen activator inhibitor-1.

  2003cited by this paper
• The role of beta-strand 5A of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin.

  2002cited by this paper
• Characterization and Comparative Evaluation of a Novel PAI-1 Inhibitor

  2002cited by this paper
• The vitronectin binding area of plasminogen activator inhibitor‐1, mapped by mutagenesis and protection against an inactivating organochemical ligand

  2002cited by this paper
• The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

  2002cited by this paper
• The Molecular Basis for Anti-Proteolytic and Non-Proteolytic Functions of Plasminogen Activator Inhibitor Type-1: Roles of the Reactive Centre Loop, the Shutter Region, the Flexible Joint Region and the Small Serpin Fragment

  2002cited by this paper
• Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1

  2002cited by this paper
• Probing the role of the F-helix in serpin stability through a single tryptophan substitution.

  2002cited by this paper
• A Regulatory Hydrophobic Area in the Flexible Joint Region of Plasminogen Activator Inhibitor-1, Defined with Fluorescent Activity-neutralizing Ligands

  2001cited by this paper
• Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001.

  2001cited by this paper
• Polymerization of Plasminogen Activator Inhibitor-1*

  2001cited by this paper
• The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin

  2001cited by this paper
• Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.

  2001cited by this paper
• Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.

  2001cited by this paper
• A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.

  2001cited by this paper
• Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.

  2001cited by this paper
• The structure of a Michaelis serpin–protease complex

  2001cited by this paper
• Plasminogen Activator Inhibitor-1 Regulates Tumor Growth and Angiogenesis*

  2001cited by this paper
• Structure of a serpin–protease complex shows inhibition by deformation

  2000cited by this paper
• Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.

  2000cited by this paper
• The plasminogen activation system in tumor growth, invasion, and metastasis

  2000cited by this paper
• The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites.

  2000cited by this paper
• Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function.

  2000cited by this paper
• Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.

  2000cited by this paper
• Vitronectin and Substitution of a β-Strand 5A Lysine Residue Potentiate Activity-neutralization of PA Inhibitor-1 by Monoclonal Antibodies against α-Helix F

  2000cited by this paper
• The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.

  1999cited by this paper
• Solvent Effects on Activity and Conformation of Plasminogen Activator Inhibitor-1

  1999cited by this paper
• Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A.

  1999cited by this paper
• Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens.

  1999cited by this paper
• An ester bond linking a fragment of a serine proteinase to its serpin inhibitor.

  1998cited by this paper
• Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.

  1998cited by this paper
• Modulation of Plasminogen Activator Inhibitor 1 by Triton X-100 – Identification of Two Consecutive Conformational Transitions

  1998cited by this paper
• Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

  1998cited by this paper
• Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits.

  1997cited by this paper
• Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.

  1997cited by this paper
• The urokinase‐type plasminogen activator system in cancer metastasis: A review

  1997cited by this paper
• Evaluation of a Low Molecular Weight Modulator of Human Plasminogen Activator Inhibitor-1 Activity

  1996cited by this paper
• Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.

  1996cited by this paper
• Molecular evolution of plasminogen activator inhibitor‐1 functional stability.

  1995cited by this paper
• The Inhibition Mechanism of Serpins

  1995cited by this paper
• A Fluorescent Probe Study of Plasminogen Activator Inhibitor-1

  1995cited by this paper
• Serpin-Protease Complexes Are Trapped as Stable Acyl-Enzyme Intermediates (*)

  1995cited by this paper
• Assays for Total Protein

  1995cited by this paper
• Fibrinolysis and thrombosis.

  1994cited by this paper
• Structural basis of latency in plasminogen activator inhibitor-1

  1992cited by this paper
• Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form.

  1991cited by this paper
• Sequence‐specific binding of the N‐terminal three‐finger fragment of Xenopus transcription factor IIIA to the internal control region of a 5S RNA gene

  1991cited by this paper
• Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene

  1990cited by this paper
• [Type 1 plasminogen activator inhibitor].

  1990cited by this paper
• Calculation of protein extinction coefficients from amino acid sequence data.

  1989cited by this paper
• Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencing

  1986cited by this paper
• [Fibrinolysis and thrombosis].

  1974cited by this paper

• Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

  2020cites this paper
• Cyclic Peptides in Neurological Disorders: The Case of Cyclo(His-Pro)

  2019cites this paper
• Synthesis and characterization of novel biodegradable water dispersed poly(ether-urethane)s and their MWCNT-AS nanocomposites functionalized with aspartic acid as dispersing agent

  2018cites this paper
• Exploring the Antimicrobial and Antitumor Potentials of Streptomyces sp. AGM12-1 Isolated from Egyptian Soil

  2017cites this paper
• Cyclodipeptides: An Overview of Their Biosynthesis and Biological Activity

  2017cites this paper
• Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1

  2016cites this paper
• Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview.

  2015cites this paper
• Biocontrol of Aspergillus Species on Peanut Kernels by Antifungal Diketopiperazine Producing Bacillus cereus Associated with Entomopathogenic Nematode

  2014cites this paper
• Three bioactive cyclic dipeptides from the Bacillus sp. N strain associated with entomopathogenic nematode.

  2014cites this paper
• Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease

  2014cites this paper
• Cyclo-(His,Leu): A new microbial diketopiperazine from a terrestrial Bacillus subtilis strain B38

  2013cites this paper
• Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1

  2013cites this paper
• Separation of Cyclic Dipeptides (Diketopiperazines) from Their Corresponding Linear Dipeptides by RP-HPLC and Method Validation

  2013cites this paper
• Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist.

  2013cites this paper
• Rapid synthesis of new block copolyurethanes derived from l-leucine cyclodipeptide in reusable molten ammonium salts: novel and efficient green media for the synthesis of new hydrolysable and biodegradable copolyurethanes

  2012cites this paper
• ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer

  2012cites this paper
• Fast and eco-friendly synthesis of new hydrolysable and biodegradable copolyurethanes derived from L-leucine cyclodipeptide and different molecular weights of PEG in TBAB under microwave irradiation

  2012cites this paper
• Synthesis and characterization of poly(ether-urethane)s derived from 3,6-diisobutyl-2,5-diketopiperazine and PTMG and study of their degradability in environment

  2012cites this paper
• Application of tin(IV) porphyrin complexes as novel catalysts for the synthesis of new copolyurethanes with cyclopeptide moiety

  2012cites this paper
• Rapid synthesis of new block copolyurethanes derived from L‐leucine‐PEG in ionic liquids under microwave irradiation

  2012cites this paper
• Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.

  2012cites this paper
• Understanding the role of plasminogen activator inhibitor type-2 (PAI-2, SerpinB2) in cancer: the relationship between biochemical properties and cellular function

  2011cites this paper
• Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives.

  2011cites this paper
• Synthesis and characterization of hydrolysable poly(ether–urethane–urea)s derived from l-leucine anhydride cyclopeptide; a green synthetic method for monomer

  2010cites this paper
• Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).

  2010cites this paper
• Characterization of a Novel Class of Polyphenolic Inhibitors of Plasminogen Activator Inhibitor-1*

  2010cites this paper
• Chemical genetics approach to identify new small molecule modulators of cell growth by phenotypic screening of Saccharomyces cerevisiae strains with a library of morpholine-derived compounds.

  2010cites this paper
• A Peptide Accelerating the Conversion of Plasminogen Activator Inhibitor-1 to an Inactive Latent State

  2008cites this paper
• Engineered Antagonists of uPA and PAI-1

  2008cites this paper
• Engineering of serpins for vascular application

  2008cites this paper
• PAI-1 - a potential therapeutic target in cancer.

  2007cites this paper
• Serpins in thrombosis, hemostasis and fibrinolysis

  2007cites this paper
• Solid-phase and microwave-assisted syntheses of 2,5-diketopiperazines: small molecules with great potential.

  2007cites this paper
• Neutralization of Plasminogen Activator Inhibitor I (PAI-1) by the Synthetic Antagonist PAI-749 via a Dual Mechanism of Action

  2007cites this paper
• Diketopiperazines : biological activity and synthesis

  2007cites this paper
• Efficient synthesis of 2,5-diketopiperazines using microwave assisted heating

  2006cites this paper
• Binding areas of urokinase‐type plasminogen activator–plasminogen activator inhibitor‐1 complex for endocytosis receptors of the low‐density lipoprotein receptor family, determined by site‐directed mutagenesis

  2006cites this paper
• Identification of selective inhibitors of VHSV from biased combinatorial libraries of N,N'-disubstituted 2,5-piperazinediones.

  2006cites this paper
• Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.

  2006cites this paper
• Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.

  2004cites this paper
• Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis

  2004cites this paper
• The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?

  2004influential citation
• Plasminogen activator inhibitor-1.

  2004cites this paper
• The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

  2004influential citation